IRVINE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the ...
Avacta Group plc, the developer of Affimer ® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global ...
CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory ...
Drug developer Avacta expects to launch a new laboratory test for the SARS-CoV-2 spike protein in the next few weeks. Did you know with a Digital subscription to Yorkshire Post, you can get access to ...
A desire for a simpler, cheaper way to do common laboratory tests for medical diagnoses and to avoid "washing the dishes" led University of Connecticut researchers to develop a new technology that ...
A desire for a simpler, cheaper way to do common laboratory tests for medical diagnoses and to avoid 'washing the dishes' led researchers to develop a new technology that reduces cost and time. The 3D ...
IRVINE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the ...
Avacta Group, a developer of Affimer biotherapeutics and reagents, announced that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the ...
Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus Avacta Group plc (AIM: AVCT), the developer of Affimer® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback